BIIBHealthcare · Drug Manufacturers - GeneralThe 36 Wall Street analysts covering Biogen, Inc. hold a median 12-month price target of $237 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Biogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BIIB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +12.9% from it.
Of the 20 most recent actions, 12 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Mizuho | Maintains | Outperform | $221 → $241 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $200 → $215 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $245 → $248 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $237 → $251 |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $222 → $231 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | $242 → $240 |
| 30 July 2026 | TD Cowen | Maintains | Buy | $215 → $225 |
| 30 July 2026 | UBS | Maintains | Buy | $225 → $240 |
| 30 July 2026 | Wedbush | Maintains | Neutral | $201 → $215 |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | $185 → $200 |
| 21 July 2026 | B of A Securities | Maintains | Neutral | — |
| 21 July 2026 | B of A Securities | Maintains | Neutral | $217 → $215 |
| 21 July 2026 | Guggenheim | Maintains | Buy | $260 → $280 |
| 21 July 2026 | Guggenheim | Maintains | Buy | — |
| 13 July 2026 | Truist Securities | Upgrade | Buy | $190 → $235 |
| 13 July 2026 | Truist Securities | Upgrade | Buy | — |
| 8 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $224 → $222 |
| 8 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $227 → $242 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIIB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 41% of US stocks
Cheaper than 53% of US stocks
Cheaper than 34% of US stocks
Higher than 35% of US stocks
Higher than 4% of US stocks
Higher than 84% of US stocks
Higher than 84% of US stocks
Higher than 67% of US stocks
Higher than 53% of US stocks
Higher than 77% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biogen announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The announcement was made from Cambridge, Mass., on Aug. 06, 2026.
Why it matters — The completion of the acquisition expands Biogen's pipeline into immunology through RayThera's small-molecule therapy programs.
Biogen beat analyst estimates on both revenue and earnings, and investors reacted favorably despite a reduction in adjusted net income guidance.
Why it matters — BIIB watchers would care because the company's quarterly results exceeded expectations, signaling operational strength even as management tempered its forward profit outlook.
Biogen Inc. released its Q2 2026 earnings call transcript, as published on Seeking Alpha.
Why it matters — BIIB watchers monitor earnings call transcripts for management's commentary on quarterly financial results and strategic outlook.
Biogen reported second-quarter adjusted earnings of $3.60 per share, surpassing the consensus estimate of $2.96, and raised its profit forecast citing growth across its Alzheimer's and rare disease portfolio.
Why it matters — The earnings beat and raised forecast signal stronger-than-expected financial performance driven by key product areas that are central to Biogen's long-term strategy.
The article reports that drugmakers' shares rose following second-quarter reports, with Teva's optimistic outlook offsetting mixed quarterly results.
Why it matters — As a fellow drugmaker, Biogen investors may monitor broader sector trends and competitor performance reflected in quarterly reports across the industry.
The 36 Wall Street analysts covering Biogen, Inc. have a median 12-month price target of $237, with estimates ranging from $165 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 36 analysts covering Biogen, Inc., 23 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biogen, Inc. 71 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Biogen, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 36 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks Biogen, Inc. 71 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIIB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $300 over the next 12 months.
Biogen, Inc. returned +55.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Biogen Inc. is a global biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological, neurodegenerative, and rare diseases.
The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Biogen Completes Acquisition of RayThera Inc.". Biogen announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The announcement was made from Cambridge, Mass., on Aug. 06, 2026.
Biogen Inc. is a global biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological, neurodegenerative, and rare diseases. Headquartered in Cambridge, Massachusetts, Biogen concentrates its portfolio on conditions such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis, and other complex immunological and neuromuscular disorders. The company markets a broad range of branded medicines, including multiple sclerosis treatments like Tecfidera, Vumerity, Avonex, Plegridy, Tysabri, and Fampyra, as well as Spinraza for spinal muscular atrophy and therapies such as Qalsody and Skyclarys for specific rare neurological indications. Biogen also participates in the biosimilars market with products like Flixabi, Imraldi, and Benepali, expanding access to biologic therapies. Operating as a single business segment, Biogen generates revenue from the discovery, development, and commercialization of these advanced therapies, serving patients across the Americas, Europe, Asia, and additional international markets.
CEO Mr. Christopher A. Viehbacher · 7,500 employees · United States · https://www.biogen.com